Intelligent Bio Solutions Inc. (INBS) is a Healthcare stock trading at $2.69 (as of 2026-08-20), with a market capitalization of $8.14M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Intelligent Bio Solutions develops non-invasive, real-time monitoring and diagnostic tests, including a saliva glucose biosensor and other biosensor platforms for conditions like diabetes management and SARS-CoV-2 detection, designed for use by patients and primary health practitioners.
The business profit model hinges on turning its biosensor and diagnostic test development into commercially used products, where it must progress from assay and platform development (glucose and other modalities) to meaningful sales and operational scale.
Business quality (Weak): Insufficient segment and operating KPI disclosure in the provided data, but the available financial snapshot shows a very weak operating result in the latest quarter alongside a positive gross margin, making commercialization and operating cost control the key focus areas.
| Price | $2.69 |
| Market Cap | $8.14M |
| Price / Book | 1.54 |
| Price / Sales | 2.05 |
| FCF Yield | -200.7% |
| Revenue (TTM) | $4.22M |
| Net Margin | -294.9% |
| Return on Equity | -235.0% |
| Debt / Equity | 0.31 |
| Current Ratio | 1.44 |
| Revenue Growth (YoY) | 38.1% |
| EPS Growth (YoY) | 322.0% |
| FCF Growth (YoY) | 21.6% |
| Altman Z-Score | -10.97 (distress) |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 32.9 |
| Top Institutional Holder | ARMISTICE CAPITAL, LLC ($434850.00) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | Harry Simeonidis |
| Employees | 50 |
| Country | US |
| IPO Date | 2020-12-23 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.